Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2026
The FDA's 2025 update to biosimilar approval streamlines the process, cutting costs and time by reducing the need for clinical trials. Learn how biosimilars differ from generics, why interchangeability matters, and what's blocking wider use in the U.S.